VANCOUVER, British Columbia and BOSTON, Dec. 18, 2018 (GLOBE NEWSWIRE) — Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) that was held yesterday.
All of the matters put forward before the shareholders, as set out in the Company’s management information circular dated November 15, 2018, were approved by the requisite majority of votes cast at the Meeting. Specifically, De Visser Gray LLP was appointed as the Company’s auditors for the ensuing year, and Jim Hutchens, Dr. Robin Atlas, Kenneth Daignault, John Vacha and Chris Bleck were appointed as directors.
The biographies of all members of the Board are available on the Company’s website at https://imaginmedical.com/directors/.
About Imagin Medical
Imagin is developing powerful new imaging solutions for the detection and visualization of cancer. The Company believes its technology will radically improve cancer care during minimally invasive procedures, improving the surgeon’s ability to visualize, identify and remove cancerous cells. Imagin’s initial target market is bladder cancer, the sixth most common cancer in the U.S., and the costliest cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, Imagin’s advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contacts:
Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: stephen@kilmerlucas.com
Jim Hutchens, President & CEO
Telephone: 833-246-2446
Email: jhutchens@imaginmedical.com